A biotech hedge fund births a new immunology company
Key Points:
- Mohit Gupta, an analyst at Adar1 Capital, proposed creating a new company focused on developing an improved long-acting antibody treatment for atopic dermatitis.
- The pitch was made to Dan Schneeberger, Adar1 Capital’s principal, in his Austin, Texas office two years ago.
- Schneeberger’s primary role is investing in existing biotech firms rather than founding new companies.